Results of a retrospective analysis of the registration status of memantine-containing medicinal products on the Ukrainian pharmaceutical market

Abstract

Alzheimer’s disease-related dementia is one of the leading neurodegenerative conditions associated with progressive cognitive decline and the need for long-term pharmacotherapy. Among approved treatment options, medicines containing memantine - a key NMDA receptor antagonist - play a central role in managing moderate to severe cognitive impairment. Therefore, the availability of these medicines on the national market is essential for ensuring adherence to clinical guidelines and maintaining the continuity of patient care.